A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NNZ-2566 in Healthy Subjects, Following Oral Administration.

Trial Profile

A Phase I, Double-Blind, Randomized, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of NNZ-2566 in Healthy Subjects, Following Oral Administration.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2012

At a glance

  • Drugs Trofinetide (Primary)
  • Indications Neurological disorders; Rett syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Nov 2012 The trial was amended to enable dosing of NNZ 2566 at a higher level, up to 100 mg/kg twice-daily, according to a Neuren Pharmaceuticals media release.
    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Aug 2012 Planned end date changed from 1 May 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top